Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2013 (Filing Date: November 8, 2013)
Context: The filing discloses the completion of a capital raise in Israel and provides an unaudited pro forma interim consolidated balance sheet dated September 30, 2013, to satisfy New York Stock Exchange (NYSE MKT) listing requirements regarding minimum shareholders' equity.
Key Financial Metrics
The filing details a specific financing transaction rather than standard operating results. Key figures include:
- Capital Raise Proceeds (Gross): NIS 21,315,000 (approximately $6,058,323.62 USD).
- Capital Raise Proceeds (Net): NIS 20,226,250 (approximately $5,748,870.19 USD) after sales commissions.
- Units Sold: 3,675 units.
- Unit Composition: Each unit consisted of 500 Ordinary Shares and 375 Series 12 Options.
- Total Securities Issued: 1,837,500 Ordinary Shares and 1,378,125 Series 12 Options.
- Price Per Unit: NIS 5,800 (approximately $1,648.52 USD).
- Exchange Rate Used: NIS 3.51830 to $1.00 USD.
Note: The filing text does not provide clear values for revenue, profit, operating cash flow, margins, or existing debt levels outside of the pro forma balance sheet attachment.
Material Changes
The primary material change is the increase in shareholders' equity resulting from the "Capital Raise" completed on October 23, 2013. The company filed an unaudited pro forma balance sheet as of September 30, 2013, giving effect to this transaction to demonstrate compliance with NYSE MKT listing standards.
Outlook, Risks, and Management Commentary
Management Commentary: The filing focuses on regulatory compliance for the NYSE MKT listing application. Management confirmed the completion of the offering and the receipt of net proceeds.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard disclosure of the capital raise mechanics and the requirement to meet listing equity thresholds.
Investor Verification Checklist
- Verify the actual cash balance impact of the NIS 20,226,250 net proceeds on the company's liquidity position.
- Review the attached Exhibit 99.1 (Pro Forma Balance Sheet) to confirm the post-transaction shareholders' equity meets NYSE MKT minimums.
- Confirm the terms and exercise price of the 1,378,125 Series 12 Options issued in the offering.
- Assess the dilution impact of the 1,837,500 new Ordinary Shares on existing shareholders.